Bayer AG (BAYRY) announced an update on their ongoing clinical study.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Bayer AG (BAYRY) has completed a real-world study titled “Real-world Sequence of Systemic Therapies and Outcomes in Patients With Metastatic Colorectal Cancer Receiving 3rd and 4th Line of Treatment.” The goal is to see how the order of later-line treatments affects survival and follow-on care in metastatic colorectal cancer, a key question for treatment value and real-world use.
The study looks at approved cancer medicines used in routine care. It focuses on regorafenib (Stivarga) and the oral combination trifluridine/tipiracil, known as TAS, with or without bevacizumab. These drugs are not experimental; the aim is to see which sequence works better for people whose cancer has already progressed.
This is an observational, retrospective cohort study using patient records from treatment centers in France, Italy, and Spain. There is no random assignment or blinding, and no extra clinic visits; researchers simply compare outcomes across different treatment orders to find patterns that may guide real-world practice.
Patient data cover those who began these third- or fourth-line sequences between January 2013 and December 2022, ensuring at least three months of follow-up. The study is listed as completed, and the latest update on ClinicalTrials was submitted on 2026-02-27, signaling that data cleaning and analysis are likely well advanced.
For investors, this update matters because it may clarify the optimal use of Bayer’s Stivarga in late-line colorectal cancer, a crowded space where modest survival gains can still support stable demand. Positive sequence insights could reinforce Stivarga’s role versus rivals like TAS-based regimens and bevacizumab combinations, supporting BAYRY’s oncology revenue and sentiment even without a new drug launch.
The study has been updated and is now completed, with further details available on the ClinicalTrials portal.
To learn more about BAYRY’s potential, visit the Bayer AG drug pipeline page.